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ABSTRACT--Objectives. Recently, nitric oxide was shown to be a mediator of penile 
erection in men and the nitric oxide donor linsidomine chlorhydrate (StN-1) was intro- 
duced as a novel treatment option i patients with erectile dysfunction. We now present 
our follow-up results with the intracavernous application of SIN-1. 
Methods. One hundred thirteen patients with erectile dysfunction of various etiologies 
and 10 normal control subjects underwent intracavernous pharmacotesting with 1 mg 
SIN-1. Of the 113 patients, 71 (62.8%) underwent additional pharmacotesting with a 
mixture of papaverine (15 mg/mL) and phentolamine (0.5 mg/mL) (P/P). Forty-eight re- 
sponders to SIN-1 were enrolled in an autoinjection program with this substance. 
Results. All normal control subjects had full rigid erections lasting 40 to 70 minutes. 
Of 113 patients, 78 (69%) had responses sufficient for intercourse with SIN-l, and the 
other 35 patients (31%) demonstrated inadequate responses. All 44 responders to SIN-1 
who also received P/P had erections sufficient for intercourse with P/P in doses of 0.25 to 
2 mL (mean, 0.6 + 0.3 mL). Six patients (13.6%) had prolonged erections with minimal 
to moderate doses of P/P. From the total of 27 patients who had erections insufficient for 
intercourse with SIN-I, 20 (74.1%) had good responses with 0.25 to 2.0 mL P/P (mean, 
1.5 + 0.5 mL). One patient (4%) had a prolonged erection with 1.0 mL P/P. After 10 to 
150 injections/patient ( otal of 1160 injections; mean, 24.1 injections), no significant 
side effects were noted with SIN-1. 
Conclusions. Our data suggest that intracavernous SIN-1 is safe and efficacious in the 
majority of patients with erectile dysfunction; however, it has a lower smooth muscle re- 
laxing effect than a combination of P/P. The absence of severe side effects, including pri- 
apisms, may be xplained by the use of a physiologic pathway for induction of the erectile 
response and the rapid intracavernous decomposition of SIN-1. 
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mols idomine  (N-ethoxycarbomyl -3- -morpho-  
l inosydninimine),  is believed to liberate nitric 
oxide nonenzymat ica l ly  (nitric oxide donor) .  
Theoretically, a nitric oxide donor may be su- 
perior to other vasoactive drugs because it may 
resemble more closely the physiologic sequence 
of events in penile erection. Our pre l iminary 
results with the intracavernous appl icat ion of 
SIN-1 suggested a possible role in the treatment 
of patients with erectile dysfunction. 5 We now re- 
port our extended follow-up with SIN-1 in the 
diagnosis and treatment of patients with erectile 
dysfunction. 
MATERIAL AND METHODS 
All patients underwent  a comprehensive and 
standardized workup for erectile dysfunction, in- 
cluding a detailed case history, physical examina- 
tion, sexual case history (questionnaire), routine 
blood tests, pharmaco-Doppler ultrasound, corpus 
cavernosum electromyogram, 6 and pharmacotest- 
ing. When indicated, pharmacocavernosometry 
and pharmacocavernography were carried out (12 
patients). 
All 113 patients (8 patients with primary and 
105 patients with secondary impotence) and 10 
normal control subjects received 1 mg SIN-1 intra- 
cavernously. Of 113 patients, 71 (62.8%) received 
additional, at least three, injections of a mixture of 
papaverine (15 mg/mL) and phentolamine (0.5 
mg/mL) (P/P) pr ior to pharmacotest ing  with 
SIN-1. Increasing doses of 0.25 to 2.0 mL were 
given according to the erectile response. All injec- 
tions were given in a supine position. Responses to 
P/P and SIN-1 were evaluated by a urologist after 
10, 20, and 30 minutes by inspection and palpation 
and graded as follows: E 0, no response; E 1, slight 
tumescence; E 2, medium tumescence; E 3, full 
tumescence but no rigidity; E 4, full tumescence 
with medium rigidity, sufficient for intercourse; 
E 5, full rigid erection. Forty-eight SIN-1 respon- 
ders entered an autoinjection program with SIN-1. 
All patients were seen as outpatients after the first 
10 injections and thereafter following each series of 
25 injections. At follow-up visits, a history and 
physical examination and routine blood tests were 
taken. 
All patients as well as the normal control subjects 
were extensively informed of the study and the 
possible side effects (prolonged erections, cav- 
ernous fibrosis, infection, cavernous necrosis, and 
systemic side effects uch as hyqootension). Written 
consent was obtained from all participants. The 
study was approved by the Ethics Committee of 
the Medizinische Hochschule Hannover. 
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The 48 SIN-] responders 
1160 self-injections (10 to 15 
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s, infection, or prolonged erections were 
All pat ients  wi th  the except ion  of 3 
;'%) were satisfied with their response to 
Three patients withdrew from the study be- 
:he quality of the erectile responses to SIN-1 
COMMENT 
i ~ntly~ nitric oxide has been identified as a me- 
io [  cavernous mooth muscle relaxation and 
te erection in vitro and in vivo 1-4 Nitric oxide 
iihesized from c-arginine by nitric oxide syn- 
i(NOS); it acts on guanylate cyclase activa- 
~hich subsequently eads to an intracellular 
ise of cyclic guanosine 3',5' monophosphate 
!p).l The intracellular eceptor for cGMP is 
f dependent protein kinase G, which is be- 
[to phosphorylate ion channels, causing in- 
iular calcium depletion and smooth muscle 
~i~ion. SIN-1 is a drug approved for the treat- 
!!of coronary spasms and for angiography of 
ilary arteries. It is believed to liberate nitric 
~nonenzymatically. The recommended dosage 
~giography '1 is 0.4 to 1 mg. Since our initial 
;: e s~[low d a dose-dependent response to SIN-1 
{more favorable results with 1 mg, all subse- 
) patients received 1 mg.5 
~6ur present series 35 of 113 patients (31%) 
to respond with erections ufficient for in- 
~rse. In our initial report 5 only 21% failed; 
our  present data are somewhat less favorable. 
may be attributed to the higher percentage of 
nts with assumed neurogenic erectile dys- 
!on in our first 63 patients, since patients with 
~minantly neurogenic impotence, that is, dia- 
ii and patients after pelvic trauma, tend to re- 
J better to intracavernous pharmacotherapy, r 
fact that nonresponders to SIN-1 showed a 
incy toward multiple risk factors and 20 of 27 
'sponders (74.1%) achieved erections uffi- 
for intercourse with P/P indicates that P/P 
~e preferable to SIN-t in patients with a mul- 
5rial origin of erectile dysfunction, that is, pa -  
i with significant arterial vascular disease and 
tic neuropathy The higher smooth muscle re- 
~, potential of P/P is also reflected by the fact 
~IN-1 nonresponders needed a significantly 
' dos{Ge of P/P than nonresponders to induce 
-~ction sufficient for intercourse (1.5 _+ 0.5 vs 
0.3 mL; p <0.0001). Our observation that 
is not effective in the majority of patients 
Zenous leakage is in accordance with the find- 
~f others, s If venous leakage is a symptom of 
lplete cavernous relaxation, further support 
en to the assumpt ion  that SIN-1 causes 
submaximum cavernous relaxation. 9 In contrast, 
SIN-1 gives excellent results in patients with (as- 
sumed) relatively intact cavernous tissue, that is, 
younger patients with primary erectile dysfunction 
and erectile dysfunction due to pelvic trauma. 
In 6 of 44 SIN-1 responders (13.6%) prolonged 
erections were seen with P/P. In contrast, SIN-1 
did not cause any prolonged erections, even in nor- 
mal subjects and in patients -who needed only min- 
imum amounts  of P/R Therefore, we consider 
SIN-1 the drug of choice in patients with proven or 
suspected increased sensitivity to other vasoactive 
agents. In addition, SIN-1 may prove to be the drug 
of choice in other subgroups of patients in the fu- 
ture (ie, impotence after pelvic surgery). If SIN-1 
fails to induce a satisfactory erectile response, other 
agents, such as P/P or prostaglandin E> should be 
administered. Possible explanations for the absent 
priapismogenic potential of SIN-1 may be a more 
physiologic induction of erection and the rapid 
local metabolism of nitric oxide.l° 
After up to 150 injections/patient, o cavernous 
fibrosis was noted; with respect o local side ef- 
fects such as intrapenile discomfort or pain, SIN-1 
compares favorably to prostaglandin E 1 and the 
combinat ion of papaverine and phentolamine.  
With prostaglandin E 1 20% to 40% of patients ex- 
perience penile pain and with P/P, although less 
intense, most patients report a slight burning sen- 
sation during administration.ll With SIN-l, no pa- 
tients reported such a discomfort, which may indi- 
cate that the substance is well tolerated by the 
cavernous tissue. This is also supported by the fact 
that no inf lammatory or fibrous reactions were 
seen after multiple intracavernous injections in the 
rabbit model, ix 
Currently, all patients at our institution under- 
going intracavernous pharmacotesting receive 1 
mg SIN-1. In case of a satisfactory erectile re- 
sponse, all patients are counseled to enter a self-in- 
jection program with SIN-1 tor a maximum reduc- 
t ion of poss ib le  s ide effects.  Pat ients  not  
responding to SIN-1 are advised to undergo phar- 
macotesting with increasing doses of papaverine 
plus phentolamine. Responders continue with this 
regimen, whereas nonresponders are offered a trial 
with intracavernous calcitonin gene-related pep- 
tide plus prostaglandin El, since this combination 
was shown to be effective in the majority of P/P 
nonresponders, x3 
In conclusion, our data suggest hat intracav- 
ernous SIN-1 is safe and efficacious in the majority 
of patients with erectile dysfunction; however, it 
has a lower smooth muscle relaxing potential than 
a combination of papaverine and phentolamine. 
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The fact that  no pro longed erect ions  were  se n 
even in pat ients  w i th  a past  h i s to ry  of  p r iap isms 
may be exp la ined  by  the more  phys io log ic  induc-  
t ion of  erect ion  w i th  a n i t r i c  ox ide  donor  and  a 
rap id  in t racavernous  decompos i t ion  of  SIN-1. 
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